INmune Bio Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, INmune Bio Inc had 21.36M in cash and cash equivalents.

INmune Bio Inc reported 8.83M in total liabilities as of the latest reported quarter, including 8.42M in current liabilities and 411.00K in non-current liabilities.

As of the latest reported quarter, INmune Bio Inc's total assets were 32.35M, consisting of 29.89M in current assets and 2.46M in non-current assets.

INmune Bio Inc reported 23.52M in total shareholders' equity as of the latest reported quarter.